Physician profile
Brian Heffelfinger
NPI 1396804290
$1,626.74
in general payments reported to CMS, 2019-2025
21 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $228 · 2021: $40.29 · 2022: $216 · 2023: $150 · 2024: $453 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $479.95 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Thea Pharma INC. | $132.43 | 2022-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $121.47 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $118.62 | 2022-2024 | Vyzulta, Zylet, Lotemax Sm |
| Johnson & Johnson Surgical Vision, INC. | $105.94 | 2020 | |
| Abbvie INC. | $99.86 | 2022-2025 | |
| Allergan, INC. | $94.80 | 2020-2021 | |
| Rxsight INC | $83.15 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $61.17 | 2019-2020 | |
| Biotissue Holdings INC. | $49.13 | 2019-2021 | |
| Oyster Point Pharma, INC. | $38.95 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $31.55 | 2024 | Idose |
| Ocular Therapeutix, INC. | $31.24 | 2023-2024 | Dextenza |
| Genentech USA, INC. | $30.25 | 2024 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $29.33 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.94 | 2024 | Eylea, Eylea Hd |
| Lumibird Medical INC. | $24.02 | 2025 | |
| Apellis Pharmaceuticals, INC. | $20.71 | 2024 | Syfovre |
| Sight Sciences, INC. | $16.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.73 | 2022 | |
| Harrow Eye, LLC | $15.43 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Heffelfinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.